Relation of Left Ventricular Ejection Fraction and Functional Capacity With Metabolism and Inflammation in Chronic Heart Failure With Reduced Ejection Fraction (from the MIMICA Study)

American Journal of Cardiology

Volumn 105, Issue 7, 2010, Pages 977-983

  Thierer, Jorge ^a   Acosta, Adriana ^a   Vainstein, Nora ^a   Sultan, Mónica ^b   Francesia, Alejandra ^c   Marino, Javier ^a   Prado, Alfredo Hirchson ^a   Guglielmone, Ramiro ^a   Trivi, Marcelo ^a   Boero, Laura ^d   Brites, Fernando ^d   Anker, Stefan ^e  

^a INSTITUTO CARDIOVASCULAR DE BUENOS AIRES   (Argentina)

^b Hospital de San Isidro   (Argentina)

^c Tornu Hospital   (Argentina)

^d UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ALBUMIN; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; PRASTERONE; SPIRONOLACTONE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BODY COMPOSITION; CATABOLISM; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FUNCTIONAL DISEASE; FUNCTIONAL STATUS; GENDER; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE METABOLISM; HUMAN; INFLAMMATION; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; NUTRITIONAL STATUS; OUTPATIENT; PRIORITY JOURNAL; RISK FACTOR; SENSITIVITY AND SPECIFICITY; WALKING;

ADIPONECTIN; AGED; C-REACTIVE PROTEIN; CHRONIC DISEASE; DEHYDROEPIANDROSTERONE; FEMALE; HEART FAILURE; HUMANS; INFLAMMATION; MALE; METABOLISM; MIDDLE AGED; STROKE VOLUME; WALKING;

EID: 77949775970     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2009.11.017     Document Type: Article

References (31)

1. Anker S.D., and von Haehling S. Inflammatory mediators in chronic heart failure: an overview. Heart 90 (2004) 464-470
2. Hunt S.A. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 46 (2005) e1-e82
3. Colin-Ramirez E., Castillo-Martinez L., Orea-Tejeda A., Asensio Lafuente E., Torres Villanueva F., Rebollar Gonzalez V., Narvaez D.R., and Dorantes Garcia J. Body composition and echocardiographic abnormalities associated to anemia and volume overload in heart failure patients. Clin Nutr 25 (2006) 746-757
4. Yndestad A., Damas J.K., Oie E., Ueland T., Gullestad L., and Aukrust P. Systemic inflammation in heart failure-the whys and wherefores. Heart Fail Rev 11 (2006) 83-92
5. Sharma R., Rauchhaus M., Ponikowski P.P., Varney S., Poole-Wilson P.A., Mann D.L., Coats A.J., and Anker S.D. The relationship of the erythrocyte sedimentation rate to inflammatory cytokines and survival in patients with chronic heart failure treated with angiotensin-converting enzyme inhibitors. J Am Coll Cardiol 36 (2000) 523-528
6. Ruggiero C., Cherubini A., Ble A., Bos A.J., Maggio M., Dixit V.D., Lauretani F., Bandinelli S., Senin U., and Ferrucci L. Uric acid and inflammatory markers. Eur Heart J 27 (2006) 1174-1181
7. Bottner A., Eisenhofer G., Friberg P., Rundqvist B., and Bornstein S.R. Serum leptin levels in heart failure patients may be altered differently according to clinical stage. Eur Heart J 21 (2000) 334-335
8. McEntegart M.B., Awede B., Petrie M.C., Sattar N., Dunn F.G., MacFarlane N.G., and McMurray J.J. Increase in serum adiponectin concentration in patients with heart failure and cachexia: relationship with leptin, other cytokines, and B-type natriuretic peptide. Eur Heart J 28 (2007) 829-835
9. Horwich T.B., Kalantar-Zadeh K., MacLellan R.W., and Fonarow G.C. Albumin levels predict survival in patients with systolic heart failure. Am Heart J 155 (2008) 883-889
10. Anker S.D., Clark A.L., Kemp M., Salsbury C., Teixeira M.M., Hellewell P.G., and Coats A.J. Tumor necrosis factor and steroid metabolism in chronic heart failure: possible relation to muscle wasting. J Am Coll Cardiol 30 (1997) 997-1001
11. Richards M., and Troughton R.W. NT-proBNP in heart failure: therapy decisions and monitoring. Eur J Heart Fail 6 (2004) 351-354
12. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., and Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985) 412-419
13. Uszko-Lencer N.H., Bothmer F., van Pol P.E., and Schols A.M. Measuring body composition in chronic heart failure: a comparison of methods. Eur J Heart Fail 8 (2006) 208-214
14. Berry C., and Clark A.L. Catabolism in chronic heart failure. Eur Heart J 21 (2000) 521-532
15. Gullestad L., Ueland T., Brunsvig A., Kjekshus J., Simonsen S., Froland S.S., and Aukrust P. Effect of metoprolol on cytokine levels in chronic heart failure-a substudy in the Metoprolol Controlled-Release Randomised Intervention Trial in Heart Failure (MERIT-HF). Am Heart J 141 (2001) 418-421
16. Anker S.D., Negassa A., Coats A.J., Afzal R., Poole-Wilson P.A., Cohn J.N., and Yusuf S. Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study. Lancet 361 (2003) 1077-1083
17. Rostagno C., Olivo G., Comeglio M., Boddi V., Banchelli M., Galanti G., and Gensini G.F. Prognostic value of 6-minute walk corridor test in patients with mild to moderate heart failure: comparison with other methods of functional evaluation. Eur J Heart Fail 5 (2003) 247-252
18. Palmieri V., Roman M.J., Bella J.N., Liu J.E., Best L.G., Lee E.T., Howard B.V., and Devereux R.B. Prognostic implications of relations of left ventricular systolic dysfunction with body composition and myocardial energy expenditure: the Strong Heart study. J Am Soc Echocardiogr 21 (2008) 66-71
19. Alonso-Martinez J.L., Llorente-Diez B., Echegaray-Agara M., Olaz-Preciado F., Urbieta-Echezarreta M., and Gonzalez-Arencibia C. C-reactive protein as a predictor of improvement and readmission in heart failure. Eur J Heart Fail 4 (2002) 331-336
20. Nagatomo Y., Yoshikawa T., Kohno T., Yoshizawa A., Anzai T., Meguro T., Satoh T., and Ogawa S. Effects of beta-blocker therapy on high sensitivity C-reactive protein, oxidative stress, and cardiac function in patients with congestive heart failure. J Card Fail 13 (2007) 365-371
21. Gielen S., Adams V., Niebauer J., Schuler G., and Hambrecht R. Aging and heart failure-similar syndromes of exercise intolerance?. Implications for exercise-based interventions. Heart Fail Monit 4 (2005) 130-136
22. Libera L.D., and Vescovo G. Muscle wastage in chronic heart failure, between apoptosis, catabolism and altered anabolism: a chimaeric view of inflammation?. Curr Opin Clin Nutr Metab Care 7 (2004) 435-441
23. Costello-Boerrigter L.C., and Burnett Jr. J.C. A new role for the natriuretic peptides: metabolic regulators of the adipocyte. J Am Coll Cardiol 53 (2009) 2078-2079
24. Moriyama Y., Yasue H., Yoshimura M., Mizuno Y., Nishiyama K., Tsunoda R., Kawano H., Kugiyama K., Ogawa H., Saito Y., and Nakao K. The plasma levels of dehydroepiandrosterone sulfate are decreased in patients with chronic heart failure in proportion to the severity. J Clin Endocrinol Metab 85 (2000) 1834-1840
25. Jankowska E.A., Biel B., Majda J., Szklarska A., Lopuszanska M., Medras M., Anker S.D., Banasiak W., Poole-Wilson P.A., and Ponikowski P. Anabolic deficiency in men with chronic heart failure: prevalence and detrimental impact on survival. Circulation 114 (2006) 1829-1837
26. Tanner H., Mohacsi P., Fuller-Bicer G.A., Rieben R., Meier B., Hess O., and Hullin R. Cytokine activation and disease progression in patients with stable moderate chronic heart failure. J Heart Lung Transplant 26 (2007) 622-629
27. Verma S., Li S.H., Badiwala M.V., Weisel R.D., Fedak P.W., Li R.K., Dhillon B., and Mickle D.A. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation 105 (2002) 1890-1896
28. Windram J.D., Loh P.H., Rigby A.S., Hanning I., Clark A.L., and Cleland J.G. Relationship of high-sensitivity C-reactive protein to prognosis and other prognostic markers in outpatients with heart failure. Am Heart J 153 (2007) 1048-1055
29. Wei L., Fahey T., Struthers A.D., and MacDonald T.M. Association between allopurinol and mortality in heart failure patients: a long-term follow-up study. Int J Clin Pract 63 (2009) 1327-1333
30. Gavin A.D., and Struthers A.D. Allopurinol reduces B-type natriuretic peptide concentrations and haemoglobin but does not alter exercise capacity in chronic heart failure. Heart 91 (2005) 749-753
31. Niebauer J. Effects of exercise training on inflammatory markers in patients with heart failure. Heart Fail Rev 13 (2008) 39-49